1. Home
  2. FENG vs NEUP Comparison

FENG vs NEUP Comparison

Compare FENG & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phoenix New Media Limited

FENG

Phoenix New Media Limited

HOLD

Current Price

$1.72

Market Cap

20.9M

Sector

Industrials

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$4.19

Market Cap

23.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FENG
NEUP
Founded
1998
1996
Country
China
United States
Employees
N/A
8
Industry
Broadcasting
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
20.9M
23.0M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
FENG
NEUP
Price
$1.72
$4.19
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
1.3K
23.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.28
$3.65
52 Week High
$3.65
$21.31

Technical Indicators

Market Signals
Indicator
FENG
NEUP
Relative Strength Index (RSI) 39.32 55.39
Support Level $1.70 $3.99
Resistance Level $2.37 $4.56
Average True Range (ATR) 0.03 0.17
MACD 0.00 0.02
Stochastic Oscillator 11.76 66.08

Price Performance

Historical Comparison
FENG
NEUP

About FENG Phoenix New Media Limited

Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: